Eosinophilic Disorders

Questions discussed in this category

Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?

Does the severity of asthma play a role in decision making?

2 Answers available

Do you utilize cytokine panels to guide treatment of patients with EGPA?

2 Answers available

What is your second line therapy for patients with EGPA with mainly pulmonary and sinonasal features who did not respond to mepolizumab 300 mg/month and still require high doses of steroid?

2 Answers available

Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?

1 Answer available

What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?

1 Answer available

What is your approach to biologic selection in a patient with resistant/persistent ABPA?

1 Answer available

How would you approach an asymptomatic older female patient with eosinophilia to 17,000, present for years, and normal eosinophilia workup including marrow and negative FLIP1?

Would you treat a patient like this with Nucala and if so, what would be your marker of success?

1 Answer available

Would you ever use dupilumab for atopic dermatitis in a patient who also has EGPA?

1 Answer available

What treatment options do you consider if eosinophilia with end organ dysfunction persists with q8 week dosing of benralizumab and you can't obtain approval for q4 week dosing?

1 Answer available

What parasites do you screen for in your workup of HES?

1 Answer available

How often do you monitor the eosinophil count after initiating anti-IL5 therapy for HAE?

1 Answer available

Would you favor treating HES manifesting with EoE with dupilumab or anti-IL5 therapy?

1 Answer available

How do you approach an isolated T-cell gene arrangement found in the setting of persistent hypereosinophilia?

If all work-up including peripheral flow, bone marrow biopsy, PET-CT returns negative, what additional management (if any) would be recommended?

1 Answer available

Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?

1 Answer available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

Papers discussed in this category

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

The New England journal of medicine, 2017-05-18

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

European journal of haematology, 2017-04

J Allergy Clin Immunol Pract, 2021 Feb 03

CD3CD4 Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited.

Eur J Haematol, 2020 May 18

Causes of hypereosinophilia in 100 consecutive patients.

Br J Haematol, 2019 Nov 13

Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome.

Br J Haematol, 2021 Jun 08

Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.

Arthritis & rheumatology (Hoboken, N.J.), 2021 Dec 30

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.

European journal of clinical investigation, 2024 Oct 10

Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta-analysis of eight studies.

Clinical and experimental rheumatology, 2019

Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma.

PloS one, 2015 Mar 26

Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Frontiers in immunology, 2022 Jun 10

Serum Proteomic Analysis Identifies SAA1, FGA, SAP, and CETP as New Biomarkers for Eosinophilic Granulomatosis With Polyangiitis.

Rheumatology (Oxford, England), 2025 Mar 01

SERPINA3, FGA, AGP1, ITIH3 and SAA1 as novel biomarkers for eosinophilic granulomatosis with polyangiitis diagnosis and activity assessment.

The Journal of allergy and clinical immunology, 2022 Jun 27

Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

Eosinophilic Disorders

Questions discussed in this category

Papers discussed in this category

Related Topics